1. |
Pramipexole for initial therapy of early Parkinson's disease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
Botulinum toxin A for cervical dystonia: improvement at a cost |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Smoking in COPD: from costs to quitting |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 5-6
Deborah Cochrane,
Preview
|
|
摘要:
Cigarette smoking is responsible for the death of 1 in 10 adults worldwide. This translates to 1 death every 8 seconds as a result of tobacco-related disease. Already a major burden on society, chronic obstructive pulmonary disease (COPD) is predicted to become 1 of the 5 leading medical burdens on society in the next 20 years. Smoking cessation is considered to be very difficult, yet it is the only way to effectively prevent the accelerated decrease in lung volume associated with COPD. Amfebutamone [bupropion; 'Zyban'], the first nicotine-free smoking cessation drug, has already been launched in the US and Europe. Studies involving patients who are otherwise healthy aside from their cigarette smoking habit show amfebutamone to be more effective than placebo as an aide to the withdrawal of cigarettes. Studies presented at the 10th Annual European Respiratory Society Congress/1st World Congress on Lung Health [Florence, Italy; August-September 2000] evaluated the health and economic consequences of smoking in patients with COPD and showed that amfebutamone is effective as a smoking cessation therapy in such patients.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
IY-81149 effectively suppresses gastric acid secretion |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
Telithromycin: an innovative solution to resistance in RTIs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 7-8
Anoma Ranaweera,
Preview
|
|
摘要:
Respiratory tract infections (RTIs) continue to represent the most common type of infection managed by healthcare providers. The emergence of multi-drug resistant strains ofStreptococcus pneumoniaeand other respiratory pathogens has become a significant problem that has complicated the management of such infections. Although the macrolide-lincosamide-streptogramin Group B (MLSB) antimicrobials are clinically valuable drugs for the treatment of RTIs caused by penicillin-resistant organisms, resistance to these antimicrobials is now emerging on a global scale, threatening their future usefulness. Telithromycin ['Ketek'], the first member of a new family of antibacterials called the ketolides, has been developed specifically to overcome this problem. Aventis Pharma presented phase III clinical data from several multinational studies at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Toronto, Canada; September 2000], the results of which indicate that oral telithromycin provides a convenient, once-daily, short-course treatment option for RTIs, including those caused by bacteria resistant to available therapies.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
Botulinum toxin A: a new approach to migraine prophylaxis? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 11-12
Kate Palmer,
Preview
|
|
摘要:
Despite the availability of a number of agents for the acute treatment of migraine attacks, some patients do not achieve adequate relief of their symptoms or they experience adverse effects when taking these medications. For such individuals, prophylactic therapy may be a suitable approach to managing their migraines. At Headache World 2000 [London, UK; September 2000], the use of IM injections of botulinum toxin A ['Botox'] as prophylaxis for migraine was discussed in a symposium sponsored by Allergan Inc.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Paclitaxel salvage therapy'feasible'in pancreatic cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1261,
2000,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|